Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

ABSTRACT Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed to tumor-associated or -specific antigens (TAAs or TSAs), in the presence of immunostimulatory molecules to induce DC maturation, followed by reinfusion into patients. Accordingly, DC vaccines can induce TAA/TSA-specific CD8+/CD4+ T cell responses. Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.

[1]  L. Zitvogel,et al.  Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy , 2022, Oncoimmunology.

[2]  L. Galluzzi,et al.  An autologous dendritic cell vaccine promotes anticancer immunity in ovarian cancer patients with low mutational burden and cold tumors. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Jennie W. Taylor,et al.  Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter , 2022, Neuro-oncology.

[4]  F. Ginhoux,et al.  Human dendritic cells in cancer , 2022, Science Immunology.

[5]  T. Matozaki,et al.  The Role of Type-2 Conventional Dendritic Cells in the Regulation of Tumor Immunity , 2022, Cancers.

[6]  A. Tong,et al.  Immunotherapy of glioblastoma: Recent advances and future prospects , 2022, Human vaccines & immunotherapeutics.

[7]  D. McNeel,et al.  Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression , 2022, Oncoimmunology.

[8]  L. Galluzzi,et al.  Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment , 2022, Nature Reviews Drug Discovery.

[9]  L. Zitvogel,et al.  Immunogenic cell stress and death , 2022, Nature Immunology.

[10]  V. Khoo,et al.  Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. , 2022, JAMA oncology.

[11]  Bin Lv,et al.  Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer , 2022, Oncoimmunology.

[12]  Dong Hyun Kim,et al.  Potential of Mycobacterium tuberculosis chorismate mutase (Rv1885c) as a novel TLR4-mediated adjuvant for dendritic cell-based cancer immunotherapy , 2022, Oncoimmunology.

[13]  F. Ginhoux,et al.  Expanding dendritic cell nomenclature in the single-cell era , 2022, Nature Reviews Immunology.

[14]  A. Coosemans,et al.  A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology , 2022, Oncoimmunology.

[15]  F. Balkwill,et al.  Harnessing cytokines and chemokines for cancer therapy , 2022, Nature Reviews Clinical Oncology.

[16]  D. Laoui,et al.  Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions , 2022, International journal of molecular sciences.

[17]  C. Figdor,et al.  Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients , 2021, Oncoimmunology.

[18]  Bo Zhang,et al.  Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers , 2021, ESMO open.

[19]  I. Grypari,et al.  Radical or Not-So-Radical Prostatectomy: Do Surgical Margins Matter? , 2021, Cancers.

[20]  D. de Ruysscher,et al.  Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study , 2021, Cancers.

[21]  Yuan-Chuan Chen,et al.  The Immunotherapy for Colorectal Cancer, Lung Cancer and Pancreatic Cancer , 2021, International journal of molecular sciences.

[22]  J. Marine,et al.  Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer , 2021, Cancer Immunology Research.

[23]  D. Lambrechts,et al.  Immunogenomic, single-cell and spatial dissection of CD8+T cell exhaustion reveals critical determinants of cancer immunotherapy , 2021, bioRxiv.

[24]  S. Aamdal,et al.  Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy , 2021, The Prostate.

[25]  V. Bagnato,et al.  Carbon-Based Materials in Photodynamic and Photothermal Therapies Applied to Tumor Destruction , 2021, International journal of molecular sciences.

[26]  A. Harari,et al.  Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers , 2021, Cancers.

[27]  D. Timmerman,et al.  Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer , 2021, Journal for ImmunoTherapy of Cancer.

[28]  Jian You,et al.  Strategy and clinical application of up-regulating cross presentation by DCs in anti-tumor therapy. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[29]  C. B. Mishra,et al.  Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure? , 2021, International journal of molecular sciences.

[30]  John E. Connolly,et al.  Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit , 2021, Cancer Immunology, Immunotherapy.

[31]  K. Radford,et al.  Conventional type 1 dendritic cells (cDC1) as cancer therapeutics: challenges and opportunities , 2021, Expert opinion on biological therapy.

[32]  L. Galluzzi,et al.  Immunological configuration of ovarian carcinoma: features and impact on disease outcome , 2021, Journal for ImmunoTherapy of Cancer.

[33]  A. Rizvanov,et al.  Recent Advances in Experimental Dendritic Cell Vaccines for Cancer , 2021, Frontiers in Oncology.

[34]  Xiao-mei Yang,et al.  A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine. , 2021, Cancer letters.

[35]  Hao-Wei Wang,et al.  Antigen Loss after Targeted Immunotherapy in Hematological Malignancies. , 2021, Clinics in laboratory medicine.

[36]  M. Salem,et al.  Targeting CD166+ lung cancer stem cells: Molecular study using murine dendritic cell vaccine. , 2021, Toxicology and applied pharmacology.

[37]  A. Hein,et al.  Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial. , 2021, Gynecologic Oncology.

[38]  H. Kourie,et al.  PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. , 2021, Immunotherapy.

[39]  Z. Hartman,et al.  Mechanisms of Therapeutic Antitumor Monoclonal Antibodies , 2021, Cancer Research.

[40]  S. Tejpar,et al.  Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy , 2021, Genes & Immunity.

[41]  U. Swami,et al.  Cancer immunotherapy: recent advances and challenges , 2021, Annals of translational medicine.

[42]  T. Kaisho,et al.  The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. , 2021, Immunity.

[43]  Fumito Ito,et al.  In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models , 2021, Journal for ImmunoTherapy of Cancer.

[44]  M. Lutz,et al.  Revisiting Current Concepts on the Tolerogenicity of Steady-State Dendritic Cell Subsets and Their Maturation Stages , 2021, The Journal of Immunology.

[45]  L. Horvath,et al.  Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer , 2021, Frontiers in Immunology.

[46]  C. Hammer,et al.  Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion , 2021, Nature Reviews Cancer.

[47]  K. Rock,et al.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation , 2021, Frontiers in Immunology.

[48]  T. Wagner,et al.  A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis , 2021, Annals of Surgical Oncology.

[49]  G. Randolph.  Dendritic cells: The first step , 2021, The Journal of experimental medicine.

[50]  I. Wistuba,et al.  PD-L1 as a biomarker of response to immune-checkpoint inhibitors , 2021, Nature Reviews Clinical Oncology.

[51]  S. Loi,et al.  Intratumoral heterogeneity in cancer progression and response to immunotherapy , 2021, Nature Medicine.

[52]  M. Bhasin,et al.  Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T-cell responses in a murine acute myeloid leukemia model , 2021, Haematologica.

[53]  Yuquan Wei,et al.  Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer , 2021, Signal Transduction and Targeted Therapy.

[54]  D. Bartlett,et al.  Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-α, and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases , 2021, Annals of Surgical Oncology.

[55]  S. Terry,et al.  Tumor hypoxia: an important regulator of tumor progression or a potential modulator of tumor immunogenicity? , 2021, Oncoimmunology.

[56]  H. Jacob,et al.  Hsp70 modulates immune response in pancreatic cancer through dendritic cells , 2021, Oncoimmunology.

[57]  D. von Laer,et al.  Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants , 2021, Oncoimmunology.

[58]  L. Galluzzi,et al.  LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells , 2021, Oncoimmunology.

[59]  Minghui Zhang,et al.  Double-edged effects of interferons on the regulation of cancer-immunity cycle , 2021, Oncoimmunology.

[60]  J. Galon,et al.  Evasion before invasion: Pre-cancer immunosurveillance , 2021, Oncoimmunology.

[61]  Guihua Chen,et al.  Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data , 2021, Oncoimmunology.

[62]  J. Shively,et al.  Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine , 2021, Oncoimmunology.

[63]  Z. Tong,et al.  Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma , 2021, Oncoimmunology.

[64]  A. Eresen,et al.  Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer , 2021, Oncoimmunology.

[65]  Yixiang Wang,et al.  Oral administration of Bifidobacterium breve promotes antitumor efficacy via dendritic cells-derived interleukin 12 , 2021, Oncoimmunology.

[66]  Allon M. Klein,et al.  Tumor-infiltrating dendritic cell states are conserved across solid human cancers , 2020, The Journal of experimental medicine.

[67]  A. Voisin,et al.  The many-sided contributions of NF-κB to T-cell biology in health and disease. , 2021, International review of cell and molecular biology.

[68]  M. Slifker,et al.  Targeted Stat2 deletion in conventional dendritic cells impairs CTL responses but does not affect antibody production , 2020, Oncoimmunology.

[69]  H. Schlüter,et al.  N-terminal VP1 Truncations Favor T = 1 Norovirus-Like Particles , 2020, Vaccines.

[70]  F. De Smet,et al.  Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma , 2020, Cancers.

[71]  L. Zitvogel,et al.  Immunomodulation by targeted anticancer agents. , 2020, Cancer cell.

[72]  B. Neyns,et al.  Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial , 2020, Vaccines.

[73]  Yuan Wu,et al.  Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future , 2020, Frontiers in Immunology.

[74]  A. Stenzinger,et al.  Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. , 2020, Cancer discovery.

[75]  N. Bhardwaj,et al.  Unexplored horizons of cDC1 in immunity and tolerance. , 2020, Advances in immunology.

[76]  T. Ashizawa,et al.  Alpha-type-1 Polarized Dendritic Cell-based Vaccination in Newly Diagnosed High-grade Glioma: A Phase II Clinical Trial , 2020, AntiCancer Research.

[77]  Young Seob Kim,et al.  Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors , 2020, Cancer Immunology, Immunotherapy.

[78]  M. Oka,et al.  Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial , 2020, Cancer Immunology, Immunotherapy.

[79]  A. Dietz,et al.  Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients , 2020, Nature Communications.

[80]  H. Sugiyama,et al.  Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial , 2020, AntiCancer Research.

[81]  F. Ginhoux,et al.  Genetic models of human and mouse dendritic cell development and function , 2020, Nature reviews. Immunology.

[82]  E. Nuryadi,et al.  Tackling Resistance to Cancer Immunotherapy: What Do We Know? , 2020, Molecules.

[83]  A. Harari,et al.  Antitumour dendritic cell vaccination in a priming and boosting approach , 2020, Nature Reviews Drug Discovery.

[84]  Zhaowu Ma,et al.  Dendritic cell biology and its role in tumor immunotherapy , 2020, Journal of Hematology & Oncology.

[85]  Susan M. Schlenner,et al.  Necroptosis in Immuno-Oncology and Cancer Immunotherapy , 2020, Cells.

[86]  R. Tussiwand,et al.  Novel concepts in plasmacytoid dendritic cell (pDC) development and differentiation. , 2020, Molecular immunology.

[87]  Y. Chen,et al.  Engineering CAR-T Cells for Next-Generation Cancer Therapy. , 2020, Cancer cell.

[88]  S. H. van der Burg,et al.  Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model , 2020, Journal for ImmunoTherapy of Cancer.

[89]  M. Mahmoudi,et al.  Dendritic Cells Currently under the Spotlight; Classification and Subset Based upon New Markers , 2020, Immunological investigations.

[90]  P. Marchetti,et al.  Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions , 2020, Journal of immunology research.

[91]  B. Neyns,et al.  A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases , 2020, Cancer Immunology and Immunotherapy.

[92]  E. Berglund,et al.  Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors , 2020, Cancer Immunology, Immunotherapy.

[93]  Yanling Liu,et al.  Silencing IDO2 in dendritic cells: A novel strategy to strengthen cancer immunotherapy in a murine lung cancer model. , 2020, International journal of oncology.

[94]  M. Weller,et al.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.

[95]  Konrad U. Förstner,et al.  IL-12 from endogenous cDC1, and not vaccine DC, is required for Th1 induction , 2020, JCI insight.

[96]  B. Ruffell,et al.  Dendritic Cells and Their Role in Immunotherapy , 2020, Frontiers in Immunology.

[97]  Xiang-rong Song,et al.  Ex vivo pulsed dendritic cell vaccination against cancer , 2020, Acta Pharmacologica Sinica.

[98]  M. Hellmann,et al.  Acquired Resistance to Immune Checkpoint Inhibitors. , 2020, Cancer cell.

[99]  E. Kleinerman,et al.  Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells , 2020, Journal for ImmunoTherapy of Cancer.

[100]  D. Shanehbandi,et al.  Dendritic cell therapy in cancer treatment; the state-of-the-art. , 2020, Life sciences.

[101]  S. Phuphanich,et al.  A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma , 2020, Journal of Clinical Neuroscience.

[102]  J. Waithman,et al.  Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy , 2020, Cells.

[103]  You-Wen He,et al.  Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients , 2020, Cancer Immunology, Immunotherapy.

[104]  W. Lowrance,et al.  Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma , 2020, Clinical Cancer Research.

[105]  H. Lyerly,et al.  DC-CIK as a widely applicable cancer immunotherapy , 2020, Expert opinion on biological therapy.

[106]  B. Neyns,et al.  TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma , 2020, Journal for ImmunoTherapy of Cancer.

[107]  C. Figdor,et al.  Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial , 2020, Cancer Immunology, Immunotherapy.

[108]  V. Paradis,et al.  PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma , 2020, Oncoimmunology.

[109]  J. Galon,et al.  Multiverse of immune microenvironment in metastatic colorectal cancer , 2020, Oncoimmunology.

[110]  S. Schleicher,et al.  Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting , 2020, Oncoimmunology.

[111]  R. Kiessling,et al.  PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates , 2020, Oncoimmunology.

[112]  E. Ullrich,et al.  Immunotherapy with NK cells: recent developments in gene modification open up new avenues , 2020, Oncoimmunology.

[113]  S. Demaria,et al.  IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection , 2020, Oncoimmunology.

[114]  R. Kiessling,et al.  Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination , 2020, Oncoimmunology.

[115]  R. Bergmann,et al.  Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy , 2020, Oncoimmunology.

[116]  E. Romano,et al.  Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors , 2020, Oncoimmunology.

[117]  P. Chang,et al.  Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer , 2020, Oncoimmunology.

[118]  G. Helmlinger,et al.  Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis , 2020, Oncoimmunology.

[119]  D. Ma,et al.  Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study , 2020, Oncoimmunology.

[120]  J. Haanen,et al.  Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination , 2020, Oncoimmunology.

[121]  J. Xia,et al.  Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection , 2020, Oncoimmunology.

[122]  C. Aspord,et al.  An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial , 2020, Oncoimmunology.

[123]  Dan Zou,et al.  Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma , 2020, Oncoimmunology.

[124]  Felicia L. Lenzo,et al.  Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity , 2020, Oncoimmunology.

[125]  M. Luo,et al.  Overexpression of microRNA-155 enhances the efficacy of dendritic cell vaccine against breast cancer , 2020, Oncoimmunology.

[126]  L. Zitvogel,et al.  Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology , 2020, Oncoimmunology.

[127]  Wei R. Chen,et al.  A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer , 2019, Oncoimmunology.

[128]  Abhishek D Garg,et al.  Type I interferons and endoplasmic reticulum stress in health and disease , 2019, International Review of Cell and Molecular Biology.

[129]  T. Luetkens,et al.  The promise of adoptive cellular immunotherapies in hepatocellular carcinoma , 2019, Oncoimmunology.

[130]  P. Agostinis,et al.  Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses. , 2020, Methods in enzymology.

[131]  Reem Saleh,et al.  Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. , 2020, Seminars in cancer biology.

[132]  Z. Ding,et al.  Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models , 2019, Cancer Immunology, Immunotherapy.

[133]  A. Alzahrani.  PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. , 2019, Seminars in cancer biology.

[134]  H. Azari,et al.  Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling , 2019, Journal of Immunotherapy for Cancer.

[135]  J. Witjes,et al.  Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer , 2019, Journal of Immunotherapy for Cancer.

[136]  D. Pe’er,et al.  Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity , 2019, Cell.

[137]  F. Belardelli,et al.  Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine , 2019, Cancer Immunology, Immunotherapy.

[138]  R. Auer,et al.  Killers 2.0: NK cell therapies at the forefront of cancer control. , 2019, The Journal of clinical investigation.

[139]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[140]  S. Spranger,et al.  Tissue Site and the Cancer Immunity Cycle. , 2019, Trends in cancer.

[141]  Brian J. Stevenson,et al.  A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients , 2019, Front. Immunol..

[142]  Takashi Nakamura,et al.  The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy , 2019, Scientific Reports.

[143]  Christopher M. Jackson,et al.  Mechanisms of immunotherapy resistance: lessons from glioblastoma , 2019, Nature Immunology.

[144]  L. Zitvogel,et al.  Trial watch: dendritic cell vaccination for cancer immunotherapy , 2019, Oncoimmunology.

[145]  Radleigh G. Santos,et al.  A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma , 2019, Clinical Cancer Research.

[146]  H. Hua,et al.  Targeting mTOR for cancer therapy , 2019, Journal of Hematology & Oncology.

[147]  E. Davila,et al.  An Anticancer Drug Cocktail of Three Kinase Inhibitors Improved Response to a Dendritic Cell–Based Cancer Vaccine , 2019, Cancer Immunology Research.

[148]  I. Amit,et al.  Plasmacytoid dendritic cells develop from Ly6D+ lymphoid progenitors distinct from the myeloid lineage , 2019, Nature Immunology.

[149]  S. Hohaus,et al.  Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial , 2019, Clinical Cancer Research.

[150]  M. Ogasawara,et al.  Phase I/II Pilot Study of Wilms' Tumor 1 Peptide‐Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer , 2019, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[151]  Shan Zhu,et al.  An effective dendritic cell‐based vaccine containing glioma stem‐like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma , 2019, International journal of cancer.

[152]  Leina Ma,et al.  Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity. , 2019, International immunopharmacology.

[153]  Patricia M. Santos,et al.  Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma , 2019, Journal of Immunotherapy for Cancer.

[154]  G. Coukos,et al.  The clinical application of cancer immunotherapy based on naturally circulating dendritic cells , 2019, Journal of Immunotherapy for Cancer.

[155]  Chun Jimmie Ye,et al.  Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity , 2019, Cell.

[156]  Young Seob Kim,et al.  A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine , 2019, Journal of Immunotherapy for Cancer.

[157]  K. Crozat,et al.  Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How? , 2019, Front. Immunol..

[158]  S. Mineishi,et al.  Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance , 2019, Front. Immunol..

[159]  T A Chan,et al.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[160]  R. Edelson,et al.  Ex vivo dendritic cell generation-A critical comparison of current approaches. , 2019, International review of cell and molecular biology.

[161]  E. Sokol,et al.  Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. , 2019, The oncologist.

[162]  A. Garg,et al.  Type I interferons and dendritic cells in cancer immunotherapy. , 2019, International review of cell and molecular biology.

[163]  G. Bepler,et al.  Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer , 2018, Cancer Immunology, Immunotherapy.

[164]  Aimin Jiang,et al.  Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment , 2018, Front. Immunol..

[165]  M. Smyth,et al.  Cancer immunoediting and resistance to T cell-based immunotherapy , 2018, Nature Reviews Clinical Oncology.

[166]  J. Aerts,et al.  Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets? , 2018, Front. Immunol..

[167]  I. Melero,et al.  Cytokines in clinical cancer immunotherapy , 2018, British Journal of Cancer.

[168]  C. Reis e Sousa,et al.  The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity , 2018, Trends in cancer.

[169]  S. Eisenbarth,et al.  Dendritic cell subsets in T cell programming: location dictates function , 2018, Nature Reviews Immunology.

[170]  L. Galluzzi,et al.  Linking cellular stress responses to systemic homeostasis , 2018, Nature Reviews Molecular Cell Biology.

[171]  M. Crittenden,et al.  Role of the immunosuppressive microenvironment in immunotherapy , 2018, Advances in radiation oncology.

[172]  J. Borst,et al.  CD4+ T cell help in cancer immunology and immunotherapy , 2018, Nature Reviews Immunology.

[173]  Robert Ivanek,et al.  Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells , 2018, Nature Immunology.

[174]  A. Karlsson-Parra,et al.  Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration , 2018, Pharmaceutical Research.

[175]  J. Kirkwood,et al.  Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma , 2018, Melanoma research.

[176]  Jun-Ho Lee,et al.  Dendritic Cell-Based Immunotherapy for Solid Tumors12 , 2018, Translational oncology.

[177]  E. Antonarakis,et al.  Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. , 2018, Future oncology.

[178]  J. Roa,et al.  Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer , 2018, Cancer Immunology, Immunotherapy.

[179]  Matthew Collin,et al.  Human dendritic cell subsets: an update , 2018, Immunology.

[180]  Patricia M. Santos,et al.  Dendritic Cell–Based Cancer Vaccines , 2018, The Journal of Immunology.

[181]  M. Essand,et al.  Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models , 2017, Oncoimmunology.

[182]  J. Wolchok,et al.  Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial , 2018, Oncoimmunology.

[183]  H. Hoogsteden,et al.  Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human , 2017, Clinical Cancer Research.

[184]  P. Agostinis,et al.  Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. , 2017, Trends in immunology.

[185]  L. Zitvogel,et al.  Trial watch: Dendritic cell-based anticancer immunotherapy , 2017, Oncoimmunology.

[186]  Evan W. Newell,et al.  Mapping the human DC lineage through the integration of high-dimensional techniques , 2017, Science.

[187]  T. Gajewski,et al.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.

[188]  Matthew L. Albert,et al.  Dying cells actively regulate adaptive immune responses , 2017, Nature Reviews Immunology.

[189]  N. Hacohen,et al.  Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors , 2017, Science.

[190]  M. Schmitt,et al.  Next-generation dendritic cell-based vaccines for leukemia patients. , 2017, Immunotherapy.

[191]  J. Sampson,et al.  Advances and challenges: dendritic cell vaccination strategies for glioblastoma , 2017, Expert review of vaccines.

[192]  L. Boon,et al.  The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity , 2016, Nature Communications.

[193]  D. Neuberg,et al.  Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions , 2016, Science Translational Medicine.

[194]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[195]  F. Ginhoux,et al.  Comparative genomics analysis of mononuclear phagocyte subsets confirms homology between lymphoid tissue-resident and dermal XCR1+ DCs in mouse and human and distinguishes them from Langerhans cells , 2016, Journal of immunological methods.

[196]  F. Ginhoux,et al.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. , 2016, Immunity.

[197]  P. Agostinis,et al.  Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation , 2016, Cell Death and Differentiation.

[198]  W. Germeraad,et al.  Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination , 2016, Mediators of inflammation.

[199]  H. Kohrt,et al.  In situ vaccination for the treatment of cancer. , 2016, Immunotherapy.

[200]  C. Gomes,et al.  Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. , 2016, Translational research : the journal of laboratory and clinical medicine.

[201]  A. Johnston,et al.  Analysis of Intracellular Trafficking of Dendritic Cell Receptors for Antigen Targeting. , 2016, Methods in molecular biology.

[202]  C. Figdor,et al.  Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells , 2015, Clinical Cancer Research.

[203]  Michael S. Diamond,et al.  Interferon-λ: Immune Functions at Barrier Surfaces and Beyond , 2015, Immunity.

[204]  P. Delvenne,et al.  HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells , 2015, International journal of cancer.

[205]  Michael Poidinger,et al.  Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow , 2015, Nature Immunology.

[206]  Jianan Ren,et al.  Microbial DNA Recognition by cGAS-STING and Other Sensors in Dendritic Cells in Inflammatory Bowel Diseases , 2015, Inflammatory bowel diseases.

[207]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[208]  Sebastian Amigorena,et al.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.

[209]  F. Osorio,et al.  Tumor cell lysates as immunogenic sources for cancer vaccine design , 2014, Human vaccines & immunotherapeutics.

[210]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[211]  Even Fossum,et al.  Human XCR1+ Dendritic Cells Derived In Vitro from CD34+ Progenitors Closely Resemble Blood Dendritic Cells, Including Their Adjuvant Responsiveness, Contrary to Monocyte-Derived Dendritic Cells , 2014, The Journal of Immunology.

[212]  Florent Ginhoux,et al.  Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny , 2014, Nature Reviews Immunology.

[213]  Z. Berneman,et al.  Clinical use of dendritic cells for cancer therapy. , 2014, The Lancet. Oncology.

[214]  Dige Andom Tesfatsion,et al.  Dendritic cell vaccine against leukemia: advances and perspectives. , 2014, Immunotherapy.

[215]  N. Giltiay,et al.  Controlling immune responses by targeting antigens to dendritic cell subsets and B cells. , 2014, International immunology.

[216]  B. Neyns,et al.  A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[217]  C. Aspord,et al.  Plasmacytoid Dendritic Cells Support Melanoma Progression by Promoting Th2 and Regulatory Immunity through OX40L and ICOSL , 2013, Cancer Immunology Research.

[218]  N. McGovern,et al.  Human dendritic cell subsets , 2013, Immunology.

[219]  C. Scheibenbogen,et al.  Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. , 2013, Blood.

[220]  J. Blay,et al.  Breast cancer‐derived transforming growth factor‐β and tumor necrosis factor‐α compromise interferon‐α production by tumor‐associated plasmacytoid dendritic cells , 2013, International journal of cancer.

[221]  P. Agostinis,et al.  Cancer immunogenicity, danger signals, and DAMPs: What, when, and how? , 2013, BioFactors.

[222]  Michael R. Green,et al.  Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. , 2013, The Journal of clinical investigation.

[223]  Miriam Merad,et al.  The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. , 2013, Annual review of immunology.

[224]  R. Steinman,et al.  Specialized role of migratory dendritic cells in peripheral tolerance induction. , 2013, The Journal of clinical investigation.

[225]  W. Oyen,et al.  Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. , 2013, Cancer research.

[226]  S. Bhattacharjee,et al.  CXCL10 Is Critical for the Generation of Protective CD8 T Cell Response Induced by Antigen Pulsed CpG-ODN Activated Dendritic Cells , 2012, PloS one.

[227]  L. Frati,et al.  Activation of dendritic cells by tumor cell death , 2012, Oncoimmunology.

[228]  O. Joffre,et al.  Cross-presentation by dendritic cells , 2012, Nature Reviews Immunology.

[229]  A. Irisawa,et al.  Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients , 2012, Journal of hepato-biliary-pancreatic sciences.

[230]  C. Figdor,et al.  Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. , 2012, Biomaterials.

[231]  Karolina Palucka,et al.  Cancer immunotherapy via dendritic cells , 2012, Nature Reviews Cancer.

[232]  Kateřina Pokorná,et al.  Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials , 2011, Journal of Translational Medicine.

[233]  F. Sallusto,et al.  Ralph M. Steinman 1943–2011 , 2011, Cell.

[234]  A. Tsung,et al.  Dendritic Cells and Damage-Associated Molecular Patterns: Endogenous Danger Signals Linking Innate and Adaptive Immunity , 2011, Journal of Innate Immunity.

[235]  J. Blay,et al.  Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. , 2011, Cancer research.

[236]  Christian A. Luber,et al.  Mouse CD8α+ DCs and human BDCA3+ DCs are major producers of IFN-λ in response to poly IC , 2010, The Journal of experimental medicine.

[237]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[238]  B. Malissen,et al.  Comparative genomics as a tool to reveal functional equivalences between human and mouse dendritic cell subsets , 2010, Immunological reviews.

[239]  L. Zitvogel,et al.  Dendritic cell-derived exosomes for cancer immunotherapy: what's next? , 2010, Cancer research.

[240]  Gavin Maxwell,et al.  Toll‐like receptor ligand activation of murine bone marrow‐derived dendritic cells , 2009, Immunology.

[241]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[242]  A. Prescott,et al.  TLR ligand–induced podosome disassembly in dendritic cells is ADAM17 dependent , 2008, The Journal of cell biology.

[243]  G. Coukos,et al.  Whole tumor antigen vaccination using dendritic cells: Comparison of RNA electroporation and pulsing with UV-irradiated tumor cells , 2008, Journal of Translational Medicine.

[244]  E. Tartour,et al.  Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients , 2008, Journal of immunotherapy.

[245]  A. Badiee,et al.  Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. , 2007, Vaccine.

[246]  D. Farkas,et al.  Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. , 2006, Cancer research.

[247]  C. Sousa,et al.  Dendritic cells in a mature age , 2006, Nature Reviews Immunology.

[248]  C. Figdor,et al.  Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. , 2005, Blood.

[249]  J. Xiang,et al.  Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer. , 2005, Current gene therapy.

[250]  A. Enk,et al.  Dendritic cells: key cells for the induction of regulatory T cells? , 2005, Current topics in microbiology and immunology.

[251]  C. Demangel,et al.  Targeting Dendritic Cells with Antigen-Containing Liposomes , 2004, Cancer Research.

[252]  M. Huang,et al.  Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor Immunity , 2004, Clinical Cancer Research.

[253]  T. Giese,et al.  Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. , 2003, Cancer research.

[254]  K. Shimizu,et al.  Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. , 2003, Cellular immunology.

[255]  P. Tyler,et al.  Liposomal delivery of antigen to human dendritic cells. , 2003, Vaccine.

[256]  Michel C. Nussenzweig,et al.  Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.

[257]  Takashi Hayashi,et al.  Therapeutic immune response induced by electrofusion of dendritic and tumor cells. , 2002, Cellular immunology.

[258]  Simon C Watkins,et al.  Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. , 2002, Journal of experimental therapeutics & oncology.

[259]  A. Enk,et al.  Immature, but not inactive: the tolerogenic function of immature dendritic cells , 2002, Immunology and cell biology.

[260]  G. Trinchieri,et al.  The Development of Murine Plasmacytoid Dendritic Cell Precursors Is Differentially Regulated by FLT3-ligand and Granulocyte/Macrophage Colony-Stimulating Factor , 2002, The Journal of experimental medicine.

[261]  R. Orentas,et al.  Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. , 2001, Cellular immunology.

[262]  J. Xiang,et al.  Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells , 2001, International journal of cancer.

[263]  Ira Mellman,et al.  Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.

[264]  M. Roncarolo,et al.  Differentiation of T Regulatory Cells by Immature Dendritic Cells , 2001, The Journal of experimental medicine.

[265]  L. Young,et al.  Efficient nonviral transfection of dendritic cells and their use for in vivo immunization , 2000, Nature Biotechnology.

[266]  A. Lanzavecchia,et al.  Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization , 2000, Nature Immunology.

[267]  E. Gilboa,et al.  Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. , 2000, Cancer research.

[268]  J. Gauldie,et al.  Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. , 1999, Cellular immunology.

[269]  A. Enk,et al.  Dendritic cell‐based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti‐melanoma immunity , 1999, The journal of gene medicine.

[270]  M. Foti,et al.  Early events in dendritic cell maturation induced by LPS. , 1999, Microbes and infection.

[271]  Laurence Zitvogel,et al.  Molecular Characterization of Dendritic Cell-Derived Exosomes , 1999, The Journal of cell biology.

[272]  M. Lotze,et al.  Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. , 1999, Cancer research.

[273]  A. Sher,et al.  The role of dendritic cells in the induction and regulation of immunity to microbial infection. , 1999, Current opinion in immunology.

[274]  Ishida,et al.  Dendritic cells transduced with wild‐type p53 gene elicit potent anti‐tumour immune responses , 1999, Clinical and experimental immunology.

[275]  Wei Chen,et al.  Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. , 1998, Journal of immunology.

[276]  J. Mulé,et al.  Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[277]  Laurence Zitvogel,et al.  Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes , 1998, Nature Medicine.

[278]  L. Falo,et al.  Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. , 1998, Journal of immunology.

[279]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[280]  D. Bigner,et al.  Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors , 1997, The Journal of experimental medicine.

[281]  F. Graham,et al.  Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. , 1997, Human gene therapy.

[282]  W. Heath,et al.  Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help , 1997, The Journal of experimental medicine.

[283]  T. Zal,et al.  Antigen-presenting cells in the thymus that can negatively select MHC class II-restricted T cells recognizing a circulating self antigen. , 1997, Journal of Immunology.

[284]  E. Gilboa,et al.  Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo , 1996, The Journal of experimental medicine.

[285]  H. Sakamoto,et al.  Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines , 1996, The Journal of experimental medicine.

[286]  M. Colombo,et al.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo , 1996, The Journal of experimental medicine.

[287]  R. Steinman,et al.  Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen , 1975, The Journal of experimental medicine.

[288]  R. Steinman,et al.  IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE , 1973, The Journal of experimental medicine.